In the last trading session, 52562.0 shares of the Opus Genetics Inc (NASDAQ:IRD) were traded, and its beta was 0.17. Most recently the company’s share price was $1.13, and it changed around -$0.03 or -2.59% from the last close, which brings the market valuation of the company to $35.67M. IRD currently trades at a discount to its 52-week high of $2.89, offering almost -155.75% off that amount. The share price’s 52-week low was $0.81, which indicates that the current value has risen by an impressive 28.32% since then. We note from Opus Genetics Inc’s average daily trading volume that its 10-day average is 0.21 million shares, with the 3-month average coming to 234.19K.
Opus Genetics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended IRD as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight.
Opus Genetics Inc (NASDAQ:IRD) trade information
Instantly IRD has showed a red trend with a performance of -2.59% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.4272 on recent trading dayincreased the stock’s daily price by 20.82%. The company’s shares are currently down -5.04% year-to-date, but still down -20.42% over the last five days. On the other hand, Opus Genetics Inc (NASDAQ:IRD) is 13.00% up in the 30-day period. We can see from the shorts that 0.8 million shares have been sold at a short interest cover period of 2.71 day(s).
Opus Genetics Inc (IRD) estimates and forecasts
Opus Genetics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -41.75 percent over the past six months and at a -165.22% annual growth rate that is well below the industry average of 16.50%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 53.36%.
IRD Dividends
Opus Genetics Inc’s next quarterly earnings report is expected to be released in February.
